Circ‐ILF2 in oral squamous cell carcinoma promotes cisplatin resistance and induces M2 polarization of macrophages
Journal of Cellular and Molecular Medicine · 2023-12 · 27 (24) · 4133-4144
DOI: 10.1111/jcmm.17998 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 20.10.2023. Verfasst von Siyuan Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Foshan Stomatological Hospital, School of Medicine, Foshan University, Foshan, China. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, RNA, Circular, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Cisplatin (CDDP) chemoresistance is one of the predominant factors in oral squamous cell carcinoma (OSCC) treatment failure. Uncovering the mechanisms underlying CDDP resistance is of great importance in OSCC therapy. Circular RNAs (circRNAs) are a newly discovered class of noncoding RNAs, which are reported to participate in the progression of various diseases, including cancer. However, the function of circRNAs in CDDP resistance in OSCC remains unclear. Quantitative reverse transcription PCR was used to search for different circRNAs between OSCC cell lines and CDDP‐resistant cell lines. The results showed that circ‐ILF2 expression was higher in CDDP‐resistant OSCC cell lines. The stability of circ‐ILF2 was also confirmed using RNase R and actinomycin D assays. Functional experiments, including cytotoxicity, apoptosis and growth rate assays, showed that upregulation of circ‐ILF2 contributes to CDDP resistance. Luciferase reporter‐gene, RNA pull‐down and quantitative real‐time PCR (RT‐qPCR) assays showed that circ‐ILF2 functions as a microRNA sponge for miR‐1252. Luciferase reporter assays, RNA pull‐down, RT‐qPCR and Western blotting showed that miR‐1252 directly targeted and regulated the expression of KLF8. Circ‐ILF2 plays an important role in CDDP resistance in OSCC. Circ‐ILF2 exerts its function through the miR‐1252/KLF8 pathway. In addition, tumour‐associated macrophages (TAM) play important roles in cancer progressions, our results showed that circ‐ILF2 in OSCC cells induced the M2 polarization of macrophages which provided new thoughts on immunotherapy. Our results suggest that circ‐ILF2 may represent a potential therapeutic target in CDDP‐resistant OSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Foshan Stomatological Hospital, School of Medicine, Foshan University, Foshan, China.
- Department of Oral and Maxillofacial Surgery, ZhuJiang Hospital, Southern Medical University, Guangzhou, China.
ORCID-Profile: Haigang Wei, Yilong Ai, Chen Zou
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Wu, S., Lv, X., Wei, H., Chen, W., Zheng, J., Li, X., Song, J., Ai, Y., & Zou, C. (2023). Circ‐ILF2 in oral squamous cell carcinoma promotes cisplatin resistance and induces M2 polarization of macrophages. Journal of Cellular and Molecular Medicine, 27(24), 4133-4144. https://doi.org/10.1111/jcmm.17998
Vancouver
Wu S, Lv X, Wei H, Chen W, Zheng J, Li X, et al. Circ‐ILF2 in oral squamous cell carcinoma promotes cisplatin resistance and induces M2 polarization of macrophages. Journal of Cellular and Molecular Medicine. 2023;27(24):4133-4144. doi:10.1111/jcmm.17998
BibTeX
@article{Wu2023,
author = {Wu, Siyuan and Lv, Xiaozhi and Wei, Haigang and Chen, Wuya and Zheng, Junming and Li, Xia and Song, Jing and Ai, Yilong and Zou, Chen},
title = {Circ‐ILF2 in oral squamous cell carcinoma promotes cisplatin resistance and induces M2 polarization of macrophages},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
volume = {27},
number = {24},
pages = {4133--4144},
doi = {10.1111/jcmm.17998}
}
EUVIMED